Published in PLoS One on September 12, 2011
HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med (2011) 6.30
Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS (2006) 5.58
Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab (2008) 3.64
Pertussis toxin-sensitive activation of p21ras by G protein-coupled receptor agonists in fibroblasts. Proc Natl Acad Sci U S A (1993) 2.51
Building bone to reverse osteoporosis and repair fractures. J Clin Invest (2008) 2.40
HIV-1 envelope protein gp120 is present at high concentrations in secondary lymphoid organs of individuals with chronic HIV-1 infection. J Infect Dis (2009) 1.82
Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERalpha or ERbeta. J Cell Biochem (2003) 1.76
Tumor necrosis factor-alpha and interleukin-1beta increase the Fas-mediated apoptosis of human osteoblasts. J Lab Clin Med (1999) 1.73
The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol (2008) 1.70
Cross-linking of CD4 molecules upregulates Fas antigen expression in lymphocytes by inducing interferon-gamma and tumor necrosis factor-alpha secretion. Blood (1994) 1.66
Revisiting immune exhaustion during HIV infection. Curr HIV/AIDS Rep (2011) 1.62
Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab (1999) 1.61
Alterations in circulating osteoimmune factors may be responsible for high bone resorption rate in HIV-infected children and adolescents. AIDS (2007) 1.49
Mechanisms of HIV-associated lymphocyte apoptosis: 2010. Cell Death Dis (2010) 1.40
Senescence-associated intrinsic mechanisms of osteoblast dysfunctions. Aging Cell (2011) 1.38
Metabolic bone disease in HIV infection. AIDS (2009) 1.36
HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation. J Med Virol (2008) 1.35
Is there enough gp120 in the body fluids of HIV-1-infected individuals to have biologically significant effects? Virology (2004) 1.23
Select HIV protease inhibitors alter bone and fat metabolism ex vivo. J Biol Chem (2002) 1.20
Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric study. Bone (1995) 1.17
Osteoimmunology--the hidden immune regulation of bone. Autoimmun Rev (2008) 1.16
Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss. Biochem Biophys Res Commun (2010) 1.13
Expression and function of TNF-family proteins and receptors in human osteoblasts. Bone (2003) 1.12
HIV proteins regulate bone marker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development. AIDS Res Hum Retroviruses (2007) 1.11
HIV and bone mineral density. Curr Opin Infect Dis (2010) 1.03
Fracture healing in HIV-positive populations. J Bone Joint Surg Br (2008) 1.03
Phytoestrogen genistein acts as an estrogen agonist on human osteoblastic cells through estrogen receptors alpha and beta. J Cell Biochem (2003) 1.02
Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis. Bone (2002) 1.01
gp120- and TNF-alpha-induced modulation of human B cell function: proliferation, cyclic AMP generation, Ig production, and B-cell receptor expression. J Allergy Clin Immunol (2000) 0.95
Acquired T-cell sensitivity to TRAIL mediated killing during HIV infection is regulated by CXCR4-gp120 interactions. AIDS (2005) 0.92
HIV type 1 alters mesenchymal stem cell differentiation potential and cell phenotype ex vivo. AIDS Res Hum Retroviruses (2010) 0.89
How much gp120 is there? J Infect Dis (2010) 0.87
Chemokine receptors and other G protein-coupled receptors. Curr Opin HIV AIDS (2009) 0.85
HIV-1 gp120 envelope protein and morphine-tubular cell interaction products modulate kidney fibroblast proliferation. J Investig Med (1998) 0.84
Role of 14-3-3epsilon, c-Myc/Max, and Akt phosphorylation in HIV-1 gp 120-induced mesangial cell proliferation. Am J Physiol Renal Physiol (2001) 0.83
HIV envelope protein gp120 induces neuropeptide Y receptor-mediated proliferation of vascular smooth muscle cells: relevance to AIDS cardiovascular pathogenesis. Regul Pept (1998) 0.83
Osteoblasts in HIV-infected patients: HIV-1 infection and cell function. AIDS (2001) 0.80
Potentiation of EBV-induced B Cell transformation by CXCR4-tropic, but not CCR5-tropic, HIV gp120: implications for HIV-associated lymphomagenesis. AIDS Res Hum Retroviruses (2010) 0.78
HIV-1 gp120 envelope protein modulates proliferation of human glomerular epithelial cells. J Cell Biochem (1999) 0.78
Osteoblastic cell lines are not susceptible to HIV-1 infection. Boll Soc Ital Biol Sper (1996) 0.78
Normal human osteoblast-like cells consistently express genes for insulin-like growth factors I and II but transformed human osteoblast cell lines do not. J Bone Miner Res (1995) 0.78
DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med (2006) 7.90
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2007) 6.76
Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev (2002) 6.38
Osteoporosis: now and the future. Lancet (2011) 5.81
Circulating osteoblast-lineage cells in humans. N Engl J Med (2005) 4.19
Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. J Bone Miner Res (2004) 4.02
Sarcoma derived from cultured mesenchymal stem cells. Stem Cells (2006) 3.40
Fat tissue, aging, and cellular senescence. Aging Cell (2010) 3.34
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest (2003) 3.09
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res (2008) 2.76
Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2008) 2.57
Building bone to reverse osteoporosis and repair fractures. J Clin Invest (2008) 2.40
Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A (2008) 2.39
Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women. J Clin Endocrinol Metab (2010) 2.33
For estimating creatinine clearance measuring muscle mass gives better results than those based on demographics. Kidney Int (2009) 2.32
MCP-1 is up-regulated in unstressed and stressed HO-1 knockout mice: Pathophysiologic correlates. Kidney Int (2005) 2.25
Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis. J Clin Invest (2003) 2.21
Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res (2005) 2.15
Contribution of in vivo structural measurements and load/strength ratios to the determination of forearm fracture risk in postmenopausal women. J Bone Miner Res (2007) 2.11
Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res (2008) 2.07
Bone turnover across the menopause transition: correlations with inhibins and follicle-stimulating hormone. J Clin Endocrinol Metab (2006) 2.04
The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev (2005) 2.03
Update on Wnt signaling in bone cell biology and bone disease. Gene (2011) 2.03
Age-dependence of femoral strength in white women and men. J Bone Miner Res (2010) 2.03
Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res (2011) 2.00
Structural determinants of vertebral fracture risk. J Bone Miner Res (2007) 1.97
Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol (2012) 1.94
Histone deacetylase 3 interacts with runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation. J Biol Chem (2004) 1.91
Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2009) 1.90
In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res (2014) 1.90
Mechanisms of sex steroid effects on bone. Biochem Biophys Res Commun (2005) 1.89
RelB cellular regulation and transcriptional activity are regulated by p100. J Biol Chem (2001) 1.87
Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab (2010) 1.87
Runx2: a master organizer of gene transcription in developing and maturing osteoblasts. Birth Defects Res C Embryo Today (2005) 1.84
FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res (2011) 1.80
Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERalpha or ERbeta. J Cell Biochem (2003) 1.76
Bone structure at the distal radius during adolescent growth. J Bone Miner Res (2009) 1.74
The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis. Endocrinology (2010) 1.74
Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. Proc Natl Acad Sci U S A (2013) 1.70
Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets (2009) 1.61
Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop. J Bone Miner Res (2009) 1.59
Role of circulating osteogenic progenitor cells in calcific aortic stenosis. J Am Coll Cardiol (2012) 1.59
Mesenchymal stem cells for bone repair and metabolic bone diseases. Mayo Clin Proc (2009) 1.59
Age- and sex-specific differences in the factor of risk for vertebral fracture: a population-based study using QCT. J Bone Miner Res (2006) 1.58
Lymphoid enhancer factor-1 and beta-catenin inhibit Runx2-dependent transcriptional activation of the osteocalcin promoter. J Biol Chem (2003) 1.57
Osteocalcin expression by circulating endothelial progenitor cells in patients with coronary atherosclerosis. J Am Coll Cardiol (2008) 1.55
Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res (2011) 1.53
Histone deacetylase inhibitors promote osteoblast maturation. J Bone Miner Res (2005) 1.51
Effects of estrogen with micronized progesterone on cortical and trabecular bone mass and microstructure in recently postmenopausal women. J Clin Endocrinol Metab (2013) 1.51
Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov (2011) 1.48
Estrogen receptor alpha and beta heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells. Mol Endocrinol (2005) 1.48
Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem (2003) 1.48
Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res (2002) 1.46
Human immunodeficiency virus type 1 protease cleaves procaspase 8 in vivo. J Virol (2007) 1.45
Blockade of HERG channels by HIV protease inhibitors. Lancet (2005) 1.44
Changes in Runx2/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells. J Bone Miner Res (2003) 1.42
Histone deacetylase 7 associates with Runx2 and represses its activity during osteoblast maturation in a deacetylation-independent manner. J Bone Miner Res (2008) 1.42
Fracture risk following bilateral orchiectomy. J Urol (2003) 1.41
Remodeling and vascular spaces in bone. J Bone Miner Res (2007) 1.39
Relationship of age to bone microstructure independent of areal bone mineral density. J Bone Miner Res (2012) 1.37
Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women. J Bone Miner Res (2007) 1.35
Relation of vertebral deformities to bone density, structure, and strength. J Bone Miner Res (2010) 1.32
Increasing options for the treatment of osteoporosis. N Engl J Med (2009) 1.32
Nonoxidative free fatty acid disposal is greater in young women than men. J Clin Endocrinol Metab (2010) 1.31
Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab (2006) 1.30
Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts. Bone (2011) 1.30
Histone deacetylase 3 depletion in osteo/chondroprogenitor cells decreases bone density and increases marrow fat. PLoS One (2010) 1.29
Human immunodeficiency virus-induced apoptosis of human hepatocytes via CXCR4. J Infect Dis (2003) 1.28
Effects of loss of steroid receptor coactivator-1 on the skeletal response to estrogen in mice. Endocrinology (2003) 1.28
Fracture risk after bilateral oophorectomy in elderly women. J Bone Miner Res (2003) 1.28
Contributions of bone density and structure to fracture risk assessment in men and women. Osteoporos Int (2005) 1.27
Characterization of circulating osteoblast lineage cells in humans. Bone (2007) 1.27
Robust QCT/FEA models of proximal femur stiffness and fracture load during a sideways fall on the hip. Ann Biomed Eng (2010) 1.26
A bone structural basis for fracture risk in diabetes. J Clin Endocrinol Metab (2008) 1.26
Bone morphogenic protein 2 directly enhances differentiation of murine osteoclast precursors. J Cell Biochem (2010) 1.26
Higher muscle protein synthesis in women than men across the lifespan, and failure of androgen administration to amend age-related decrements. FASEB J (2008) 1.24
Population-based analysis of the relationship of whole bone strength indices and fall-related loads to age- and sex-specific patterns of hip and wrist fractures. J Bone Miner Res (2005) 1.24
Regulation of gene expression in osteoblasts. Biofactors (2010) 1.23
Skeletal effects of estrogen are mediated by opposing actions of classical and nonclassical estrogen receptor pathways. J Bone Miner Res (2005) 1.23
Cortical porosity identifies women with osteopenia at increased risk for forearm fractures. J Bone Miner Res (2014) 1.21
High serum IGFBP-2 is predictive of increased bone turnover in aging men and women. J Bone Miner Res (2007) 1.21
Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men. Diabetes Care (2007) 1.20
MicroRNA functions in osteogenesis and dysfunctions in osteoporosis. Curr Osteoporos Rep (2013) 1.19
Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women. Bone (2011) 1.19
Female reproductive system and bone. Arch Biochem Biophys (2010) 1.19
Osteoporosis assessment by whole body region vs. site-specific DXA. Osteoporos Int (2005) 1.17
Histone deacetylases in skeletal development and bone mass maintenance. Gene (2010) 1.16
Renal hemodynamic, inflammatory, and apoptotic responses to lipopolysaccharide in HO-1-/- mice. Am J Pathol (2007) 1.16
p68 (Ddx5) interacts with Runx2 and regulates osteoblast differentiation. J Cell Biochem (2008) 1.16
Dose-response of estrogen on bone versus the uterus in ovariectomized mice. Eur J Endocrinol (2004) 1.16
The formin-homology-domain-containing protein FHOD1 enhances cell migration. J Cell Sci (2003) 1.13
Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor. J Clin Invest (2005) 1.13
Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. J Biol Chem (2001) 1.13
Renal upregulation of HO-1 reduces albumin-driven MCP-1 production: implications for chronic kidney disease. Am J Physiol Renal Physiol (2006) 1.12